Results 231 to 240 of about 24,478 (263)
Some of the next articles are maybe not open access.
Pediatric Drugs, 2009
Caspofungin is the first echinocandin to be approved for the treatment of fungal infections in pediatric patients. The antifungal properties of caspofungin result from interference with fungal cell-wall integrity. In vitro, caspofungin is fungicidal against Candida spp.
Karly P. Garnock-Jones, Susan J Keam
openaire +3 more sources
Caspofungin is the first echinocandin to be approved for the treatment of fungal infections in pediatric patients. The antifungal properties of caspofungin result from interference with fungal cell-wall integrity. In vitro, caspofungin is fungicidal against Candida spp.
Karly P. Garnock-Jones, Susan J Keam
openaire +3 more sources
Caspofungin in the treatment of invasive fungal infections
Intensive and Critical Care Nursing, 2006Caspofungin is a member of a new class of antifungals called Echinocandins and is the first to have marketing authorisation in the United Kingdom. This article reviews the clinical efficacy, side effect profile, dosing and administration schedule of caspofungin.
Simon Keady, Meera Thacker
openaire +3 more sources
Journal of Infection, 2005
The objective was to prospectively assess the efficacy and safety of caspofungin as salvage therapy for invasive aspergillosis in patients enrolled in the caspofungin compassionate-use study.Forty-eight patients with invasive Aspergillus infections (36 with pulmonary infection, 12 with extrapulmonary or disseminated infection) were enrolled in this ...
Arlene Taylor +4 more
openaire +3 more sources
The objective was to prospectively assess the efficacy and safety of caspofungin as salvage therapy for invasive aspergillosis in patients enrolled in the caspofungin compassionate-use study.Forty-eight patients with invasive Aspergillus infections (36 with pulmonary infection, 12 with extrapulmonary or disseminated infection) were enrolled in this ...
Arlene Taylor +4 more
openaire +3 more sources
Caspofungin therapy in immunocompromised children and neonates
Expert Review of Anti-infective Therapy, 2011The prevalence of invasive fungal infections is increasing and the infections are becoming a major problem in immunocompromised children and neonates. Fortunately, there has been a recent surge in the development of new antifungal agents. Caspofungin, the first licensed echinocandin, is a novel class of antifungal and is approved for use in children 3 ...
Nuran Salman +2 more
openaire +3 more sources
Experiences with the use of caspofungin in paediatric patients
Mycoses, 2008SummaryInvasive fungal infections are important causes for treatment‐related morbidity and mortality in severely immunocompromised paediatric patients with haematological malignancies or in children undergoing haematopoietic stem cell transplantation. In addition, neonates, in particular preterm infants, are at risk for invasive mycoses.
Andreas H. Groll, Thomas Lehrnbecher
openaire +3 more sources
Caspofungin for treatment of invasive aspergillus infections
Mycoses, 2008SummaryInvasive aspergillosis showed an increasing incidence during the last decades. Especially for immune‐suppressed haematological patients as well as for solid organ transplant recipients, this infection remains a life‐threatening complication.
Werner J. Heinz, H. Einsele
openaire +3 more sources
SAFETY EXPERIENCE WITH CASPOFUNGIN IN PEDIATRIC PATIENTS
Pediatric Infectious Disease Journal, 2009We analyzed the caspofungin safety experience in 5 clinical registration studies in 171 pediatric patients, 1 week to 17 years of age. Caspofungin was administered for 1 to 87 (mean 12.1) days. The most common drug-related adverse events were fever, increased AST, increased ALT, and rash; few events were serious or required treatment discontinuation ...
Thomas Lehrnbecher +13 more
openaire +3 more sources
Caspofungin: when and how? The microbiologist’s view
Mycoses, 2011SummaryThe echinocandins are antifungal agents, which act by inhibiting the synthesis of β‐(1,3)‐d‐glucan, an integral component of fungal cell walls. Caspofungin, the first approved echinocandin, demonstrates good in vitro and in vivo activity against a range of Candida species and is an alternative therapy for Aspergillus infections.
Cornelia Lass-Flörl +2 more
openaire +3 more sources
Caspofungin in a pediatric patient with persistent candidemia
Pediatric Critical Care Medicine, 2004To describe the response of a child with persistent fungemia to caspofungin, a member of the echinocandin class of antifungals.Descriptive case report.Pediatric intensive care unit at a university teaching hospital.A 3-yr-old female with persistent candidemia.After >5 wks of persistent candidemia, caspofungin was added to an antifungal regimen that ...
Karin K. Wertz, Robert K. Pretzlaff
openaire +3 more sources